| 查看: 945 | 回复: 4 | ||
| 【奖励】 本帖被评价3次，作者_菜菜子增加金币 2.4 个 | ||
[资源]
肝癌细胞中的循环肿瘤生物标记物研究
|
||
|
Circulating biomarkers in hepatocellular carcinoma Abstract Purpose Our aims are to determine levels of circulating cellular and protein biomarkers in hepatocellular carcinoma (HCC) patients and to analyse any relationships with clinical parameters. Methods Fifty-four consenting patients were recruited.Circulating tumour cells (CTCs) were enumerated (by Cell-Search) and characterised via filtration [by isolation by size of epithelial tumour cells (ISET)] with downstream immunohistochemistry (IHC). Glypican-3 (GPC3) expression in tumour biopsies and CTCs (by IHC) was compared, and levels of circulating caspase-cleaved and full-length cytokeratin 18 (CK18, measured using M30 and M65 ELISAs) were examined as a putative prognostic factor and marker of tumour burden. Results CTCs were identified in 14 out of 50 (28 %) patients by CellSearch and in 19 out of 19 (100 %) patients by ISET. The presence of GPC3-positive CTCs by ISET was 100 % concordant with the presence of GPC3-positive cells in the original tumour (n = 5). No statistically significant correlations were observed between CTC number and clinical characteristics, although trends were noted between CTC subtypes, Child–Pugh score and tumour node metastasis stage. Serum M30 and M65 levels (as continuous variables) significantly correlated with overall survival (OS)in a univariate analysis (p = 0.003 and p < 0.001, respectively);M65 levels remained statistically significant in a multivariate analysis (p = 0.029). Conclusions This is the first study to detect GPC3-positive CTCs in HCC, important for drug development with this target. The significant association of circulating CK18 with OS in HCC further exemplifies the utility of circulating biomarkers in cancer. Materials and methods Patients Sequential patients with a diagnosis of HCC were recruited to the study at two centres: The Christie NHS Foundation Trust, Manchester, UK, and North Manchester General Hospital, Manchester, UK. Patients either had no antitumour therapy within 4 weeks, or had evidence of progressive disease if prior therapy had been received and were awaiting further therapy. Clinical data collected included age, sex, Child–Pugh score, serum alpha-fetoprotein (AFP), performance status (PST), viral status, radiological extent of disease, time to progression and overall survival (OS). In addition, treatment history, tumour node metastasis (TNM) staging, Okuda stage, Barcelona stage (BCLC) and aetiological risk factors were collated. Samples After informed consent, a single blood draw of up to 30 ml was taken for biomarker analysis at baseline (defined as 4 weeks after any previous treatment, or evidence of progressive disease if therapy had been received and awaiting further therapy or supportive care only). Serum was isolated from 10 ml coagulated whole blood (collected in serum gel tubes) for analysis of the levels of full-length and/or caspase-3-cleaved cytokeratin 18 (CK18) using the M65 and M30 ELISAs, respectively; 10 ml blood was sampled into a CellSave tube (Veridex) for CTC enumeration by CellSearch, and wherever possible 10 ml (EDTA ) was sampled for analysis using the filtration-based ISET device[8]. Tumour biopsies were also obtained from 12 patients in order to compare GPC3 expression levels in CTCs with tumour at the time of diagnosis. Cell lines and antibodies SK-HEP-1 HCC cells (GPC3-negative) that had been transfected with human GPC3 cDNA were used as positive controls:SK-03 was a high expresser of GPC3, and SK-PCA13a had intermediate expression of GPC3 [9]. These cell lines were provided by Chugai Pharmaceutical Co., Ltd. Human Vascular Endothelial Cells (HUVEC) were used as endothelial cell controls to allow exclusion of circulating endothelial cells (CECs) in the CTC assay following CTC enrichment by ISET. All cell lines were cultured according to standard protocols. A mouse monoclonal antibody against GPC3 (mGC33) for immunohistochemical (IHC) analysis of tissue biopsies and of CTCs captured on ISET filters was provided by Chugai Pharmaceutical Co., Ltd. [10]. The cell lines and mGC33 antibody were used to validate GPC3 immunohistochemical assays in tissue and in cells. Enumeration and assessment of GPC3 status of CTCs CTCs were enumerated using the CellSearch platform in blood samples from 50 patients. The CellSearch methodology has been described previously [11, 12] and is based on the immunomagnetic capture of epithelial adhesion molecule (EpCAM) positive cells followed by immunophenotyping of cytokeratin, DAPI and CD45 in cells isolated from a 7.5-ml blood volume. CTCs are classed as CK+,DAPI+ and CD45?. In order to establish GPC3 expression in CTCs, an AF-488-conjugated antibody against GPC3 (mGC33) was also added to the samples in the fourth channel of the CellSearch at a concentration of 4 μg/test. The exposure time for signal detection of GPC3 was 0.4 s. This enabled the enumeration of GPC3-positive CTCs as a proportion of the total CTC count in 7.5 ml blood. |
回复此楼» 本帖附件资源列表
-
欢迎监督和反馈：小木虫仅提供交流平台，不对该内容负责。
本内容由用户自主发布，如果其内容涉及到知识产权问题，其责任在于用户本人，如对版权有异议，请联系邮箱：xiaomuchong@tal.com - 附件 1 : 肝癌细胞中的循环生物标记物研究_-铂悦仪器-2015.pdf
2016-02-01 11:44:00, 2.26 M
» 猜你喜欢
多糖送核磁不溶解
已经有3人回复
-
求助2024JCR期刊分区完整目录
已经有3人回复
-
内分泌系统/代谢和营养支持论文润色/翻译怎么收费?
已经有73人回复
-
吉林大学白求恩第三医院马连君教授课题组招收2026年消化内科方向专博研究生
已经有2人回复
-
吉林大学白求恩第三医院马连君教授课题组招收2026年消化内科方向专博研究生
已经有1人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 2012年度国家杰出青年科学基金建议资助项目申请人名单
已经有12人回复
- 关于公布2012年度国家杰出青年科学基金建议资助项目申请人名单的通告
已经有8人回复
- 2011年度国家杰出青年科学基金建议资助项目申请人名单
已经有0人回复
- 2011年杰青名单及立项
已经有1人回复
- 2011年度国家杰出青年科学基金名单已公布，所以8月19日公布面上青年地区基金
已经有50人回复
- 关于公布2011年度国家杰出青年科学基金建议资助项目申请人名单的通告
已经有21人回复
- 关于公布2011年度国家杰出青年科学基金建议资助项目申请人
已经有65人回复
- 【资源】普外科歌诀
已经有2人回复
- 【原创】2011西医综合的基本概况及常用复习方法——医学考研必读
已经有5人回复
- 【资源】600个重复多年考的知识点（执业）
已经有4人回复
- 【转帖】抗肿瘤药物的分类和临床应用
已经有29人回复
5楼2016-03-23 12:39:14
简单回复
2016-02-01 17:22
回复
五星好评 顶一下，感谢分享！
2016-02-02 15:40
回复
五星好评 顶一下，感谢分享！
silongs4楼
2016-03-23 11:41
回复
五星好评 顶一下，感谢分享！
50